Vyteris, Inc. (VYTR.OB) Obtains Exclusive License to Powerful New Complementary Transdermal Drug Delivery Technology
Vyteris, www.vyteris.com – developers of the revolutionary LidoSite® active transdermal drug delivery patch, disclosed details of an agreement with Georgia Institute of Technology’s Georgia Tech Research Corporation today. The agreement grants VYTR the option to exclusively license a patented thermal ablation and microdevice fabrication technology developed at Georgia Tech, which will be used to enhance transdermal drug delivery by increasing skin permeability from delivery of high molecular weight compounds. President and CEO of VYTR, Haro Hartounian, Ph.D., called access to these innovative technologies a real boost to the Company’s already robust transdermal capabilities, noting how the new technologies are complementary…